Chemclin Diagnostics Co. Ltd. A - Asset Resilience Ratio
Chemclin Diagnostics Co. Ltd. A (688468) has an Asset Resilience Ratio of 15.34% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Chemclin Diagnostics Co. Ltd. A leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Chemclin Diagnostics Co. Ltd. A's Asset Resilience Ratio has changed over time. See Chemclin Diagnostics Co. Ltd. A (688468) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Chemclin Diagnostics Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688468 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥270.55 Million | 15.34% |
| Total Liquid Assets | CN¥270.55 Million | 15.34% |
Asset Resilience Insights
- Good Liquidity Position: Chemclin Diagnostics Co. Ltd. A maintains a healthy 15.34% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Chemclin Diagnostics Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Chemclin Diagnostics Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Chemclin Diagnostics Co. Ltd. A (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Chemclin Diagnostics Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.11% | CN¥301.22 Million ≈ $44.08 Million |
CN¥1.76 Billion ≈ $257.68 Million |
-10.68pp |
| 2024-12-31 | 27.78% | CN¥509.00 Million ≈ $74.48 Million |
CN¥1.83 Billion ≈ $268.10 Million |
+1.97pp |
| 2023-12-31 | 25.82% | CN¥470.00 Million ≈ $68.78 Million |
CN¥1.82 Billion ≈ $266.41 Million |
-14.59pp |
| 2022-12-31 | 40.41% | CN¥643.00 Million ≈ $94.09 Million |
CN¥1.59 Billion ≈ $232.84 Million |
-2.43pp |
| 2021-12-31 | 42.84% | CN¥613.00 Million ≈ $89.70 Million |
CN¥1.43 Billion ≈ $209.39 Million |
+10.21pp |
| 2020-12-31 | 32.63% | CN¥328.57 Million ≈ $48.08 Million |
CN¥1.01 Billion ≈ $147.33 Million |
-15.68pp |
| 2019-12-31 | 48.32% | CN¥480.00 Million ≈ $70.24 Million |
CN¥993.39 Million ≈ $145.36 Million |
-- |
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more